BCPCBasic Materials · Specialty ChemicalsThe 3 Wall Street analysts covering Balchem Corp. hold a median 12-month price target of $213 — +22.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 13 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Balchem Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Value (49): The shares cost a lot relative to the profits and assets behind them.
Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BCPC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +22.7% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $215 → $210 |
| 3 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $190 → $215 |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 May 2026 | HC Wainwright & Co. | Maintains | Buy | $5.10 → $5.16 |
| 24 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2025 | Rothschild & Co | Initiates | Neutral | — |
| 22 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 20 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 July 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 June 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Feb 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BCPC appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Balchem Corp. returned +11.0% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 23% of US stocks
Cheaper than 23% of US stocks
Cheaper than 14% of US stocks
Higher than 50% of US stocks
Higher than 55% of US stocks
Higher than 45% of US stocks
Higher than 81% of US stocks
Higher than 77% of US stocks
Higher than 70% of US stocks
Higher than 89% of US stocks
Higher than 81% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Balchem Corp. has a market value of $5.5B and an enterprise value of $5.6B.
Revenue in the twelve months to 31 Mar 2026: $1.1B. The latest quarter grew 8.6% year on year.
Net income over the same four quarters: $158.1M, a 15.0% net margin.
Diluted earnings per share, trailing twelve months: $4.87.
Free cash flow in the twelve months to 31 Mar 2026: $176.0M, after $44.2M of capital spending.
Balchem Corp. spent $118.0M on share buybacks and $30.8M on dividends in the twelve months to 31 Mar 2026.
Trailing P/E: 32.7×; forward P/E: 27.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.22%, paying out 18% of earnings.
Balchem Corp. employs 1,430 people — $739K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Balchem Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Balchem reported a strong third quarter, with record net income of $46.7 million, revenue growth of 8.6%, and adjusted EBITDA up 12.5% to $80.3 million. Human Nutrition & Health led results, with revenue up 8% and operating income up 11%.
Why it matters — The results highlight growth and operating strength, particularly in Balchem’s Human Nutrition & Health segment.
Balchem Corporation announced it will participate in Baird's Global Industrial Conference on November 11, 2026.
Why it matters — The announcement informs BCPC watchers of the company's scheduled participation in an industry conference.
MarketBeat reports that inflation rose in September 2026, with the Consumer Price Index increasing 0.6%, up from 0.4% in August, despite the Federal Reserve raising interest rates. The article notes that cost pressures vary across goods and companies, with energy and gasoline prices among the fastest to rise.
Why it matters — A BCPC watcher may find the differing effects of inflation relevant when assessing the cost environment for companies, though the excerpt does not describe Balchem specifically.
Balchem reported quarterly sales growth of 8.6% and free cash flow of $57.9 million, alongside growing earnings, low borrowings, and ongoing share buybacks. The Seeking Alpha author’s DCF valuation puts the stock at roughly $88, versus a cited current price of $177, and describes it as fully priced.
Why it matters — BCPC watchers may weigh the reported operating and cash-flow strength against the author’s view that the shares are substantially overvalued.
Balchem reported third-quarter net sales of $291 million, up 8.6% year over year. Human nutrition and health segment sales rose 8.1% to $188 million.
Why it matters — The reported sales growth provides BCPC watchers with an update on company-wide and human nutrition and health segment performance.
The 3 Wall Street analysts covering Balchem Corp. have a median 12-month price target of $213, with estimates ranging from $175 to $254. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Balchem Corp., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Balchem Corp. 91 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Balchem Corp. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +22.7% from the last close, and Ticker Nerd's factor model ranks Balchem Corp. 91 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Balchem Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCPC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $254 over the next 12 months.
Balchem Corp. returned +11.0% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Balchem Corporation is a specialty ingredients and solutions company that develops, manufactures, and distributes performance products for nutrition, food, pharmaceuticals, animal health, medical device sterilization, plant nutrition, and industrial applications. The company operates through three main segments: Human Nutrition and Health, which supplies ingredients and delivery systems used in food, beverage, and supplement formulations; Animal Nutrition and Health, which provides nutritional ingredients and technologies for livestock and companion animal markets; and Specialty Products, which includes packaged performance gases and chemical products used in healthcare and other industrial settings.
The most recent item we track (Seeking Alpha, 5 Nov 2026): "Balchem: Solid Q3 Performance Support Buy Rating". Balchem reported a strong third quarter, with record net income of $46.7 million, revenue growth of 8.6%, and adjusted EBITDA up 12.5% to $80.3 million. Human Nutrition & Health led results, with revenue up 8% and operating income up 11%.
Balchem Corporation is a specialty ingredients and solutions company that develops, manufactures, and distributes performance products for nutrition, food, pharmaceuticals, animal health, medical device sterilization, plant nutrition, and industrial applications. The company operates through three main segments: Human Nutrition and Health, which supplies ingredients and delivery systems used in food, beverage, and supplement formulations; Animal Nutrition and Health, which provides nutritional ingredients and technologies for livestock and companion animal markets; and Specialty Products, which includes packaged performance gases and chemical products used in healthcare and other industrial settings. Balchem Corporation serves customers worldwide by combining formulation expertise, ingredient functionality, and application-specific technologies. Founded in 1967 and headquartered in Montvale, New Jersey, Balchem Corporation plays a broad role in specialty ingredient supply chains across health, nutrition, and industrial markets.
CEO Mr. Theodore Lee Harris · 1,430 employees · United States · https://www.balchem.com
